Avelumab
Bavencio · Anti-PD-L1 antibody
ICI-associated AIN.
Tecentriq · ATEZO
Anti-PD-L1 antibody · approved 2016 · 15 citations · FAERS AKI reporting ROR 2.03 (95% CI 1.89–2.19, 752 AKI reports)
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
An anti-PD-L1 antibody that triggers immune-mediated acute interstitial nephritis, occasionally glomerular disease.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Across the checkpoint-inhibitor class, any acute kidney injury occurs in roughly 15-17% of treated patients in cohort studies, while clinically significant immune-related AKI (most often acute interstitial nephritis) affects a smaller subset (commonly a few percent). Meta-analysis suggests anti-PD-L1 agents like atezolizumab carry somewhat lower AKI risk than anti-PD-1 agents; PD-L1-specific rates are not precisely separated. A separate real-world cohort of 1,037 ICI-treated patients supplies the drug-attributable denominator this class otherwise lacks: 18.2% developed AKI of any cause, but only 3.6% (37 patients) had AKI attributed to the checkpoint inhibitor itself — a class figure, not an atezolizumab-specific one.Source: Lumlertgul et al., Eur J Cancer 2023 (class-level ICI-attributed AKI 3.6%; agent-specific AIN rate not separately quantified)
Typically weeks to a few months out (median ~3–4 months), later than classic drug AIN.
Distilled from: “Typically weeks to a few months after initiation (median time to checkpoint-inhibitor AKI is on the order of 3-4 months, characteristically later than classic drug AIN).”
In the multicenter ICI-AKI cohort ~22% were rechallenged and ~23% of those developed recurrent AKI — feasible but an individualized, co-managed decision. PMID 31896554 (opens PubMed in a new tab)
Class-level checkpoint-inhibitor AKI recovery: in a 138-patient multicenter ICI-AKI cohort, complete, partial, and no recovery of kidney function occurred in roughly 40%, 45%, and 15% of patients respectively. Two covariates carried a better renal prognosis — treatment with steroids, and the PRESENCE of a concomitant tubulointerstitial-nephritis-causing medication (69% of patients were on one). The second is an observational association, not an intervention: the cohort analysed no effect of stopping that drug, and the likeliest reading is that a competing culprit makes the ICI a less certain cause. Rechallenge is feasible in selected patients but recurrent AKI occurs in about a quarter.PMID 31896554 (opens PubMed in a new tab)
Distilled from the agent's cited literature — educational, not a substitute for the primary sources.
Recovery across agentsThis agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Acute tubulointerstitial nephritis is the dominant renal lesion in immune checkpoint inhibitor-associated AKI, seen in 82.7% (125/151) of biopsied cases in the largest multicenter cohort; anti-PD-L1 agents such as atezolizumab carry a lower AKI risk than anti-PD-1 agents PMID 34625513 (opens PubMed in a new tab)
Checkpoint inhibitor-associated glomerular disease (FSGS, minimal-change/podocytopathy, membranous, pauci-immune GN) is case-level and far less common than AIN PMID 37973491 (opens PubMed in a new tab)
Case-level immune-related (irAE) cystitis - immune-mediated, not acrolein toxicity.
A monotherapy case with endocrinopathies excluded; the SCLC indication drives much of the reporting.
Tap a signature to trace where it strikes the nephron.
Representative incidence
Acute Interstitial Nephritis strikes: Interstitium.
Acute Interstitial Nephritis
Immune-mediated inflammation of the renal interstitium — the signature kidney injury of checkpoint inhibitors.
Humanized IgG1 monoclonal antibody blocking programmed death-ligand 1 (PD-L1), interrupting PD-1/PD-L1 (and PD-L1/B7.1) inhibitory signaling to restore antitumor T-cell activity. Used across lung, urothelial, hepatocellular, and other cancers, often with bevacizumab or chemotherapy.
27 grade-indexed syndromes across 11 organ systems, written for checkpoint blockade as a class rather than per agent — where a rate differs between anti-PD-1, anti-PD-L1, anti-CTLA-4 and combination therapy, the card names the class it was measured in.
Class-level context for the major non-renal toxicities of the Anti-PD-L1 antibody class.
Endocrine
Thyroiditis, hypophysitis, diabetes
Gastrointestinal
Diarrhea, colitis, mucositis, perforation
Hepatic / Liver
Transaminitis, hepatitis, VOD/SOS
Pulmonary
Pneumonitis, ILD, effusions, hypertension
Dermatologic
Rash, HFS, SJS/TEN, vitiligo
13 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Non-PubMed sources — conference abstracts (e.g. ASN Kidney Week, badged Abstract) and case reports from non-indexed field journals (e.g. Journal of Onco-Nephrology, badged Journal). Included for completeness; weigh below peer-reviewed PubMed citations.
Kidney rows of the label's dosage tables
From the TECENTRIQ label (Oct 2026) · DailyMed
The rows that name proteinuria, nephrotic syndrome, creatinine, creatinine clearance, renal or nephritis together with a withhold, reduce, resume or discontinue instruction, reproduced cell for cell. A merged cell is written out on each row it covers. The tables' footnotes are not reproduced, and they can hold the conditions for resuming: read the full table on DailyMed. A cell marked fn carries one of those footnotes on the label. Educational only, not medical advice.
| Adverse Reaction | Severityfn | Dosage Modification |
|---|---|---|
| Nephritis with Renal Dysfunction | Grades 2 or 3 increased blood creatinine | Withholdfn |
| Nephritis with Renal Dysfunction | Grade 4 increased blood creatinine | Permanently discontinue |
Immune-related nephritis is managed grade by grade on the atlas's kidney irAE card; this block does not restate it.
Everything below is FAERS — adverse events someone chose to report, about 40,046 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Reported with a death outcome
10,116 of 40,046 reports
Reported with hospitalization
16,934 of 40,046 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial · 5 of the 40,046 reports predate 2015 and are not drawn.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Atezolizumab sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Bavencio · Anti-PD-L1 antibody
ICI-associated AIN.
Libtayo · Anti-PD-1 antibody
ICI-associated AIN.
Jemperli · Anti-PD-1 antibody
ICI-associated AIN.
Imfinzi · Anti-PD-L1 antibody
ICI-associated AIN.
Loqtorzi · PD-1 immune checkpoint inhibitor
First FDA-approved drug for nasopharyngeal carcinoma; renal risk is class-typical immune-mediated interstitial nephritis.
Unloxcyt · PD-L1 immune checkpoint inhibitor
PD-L1 blockade for cutaneous SCC — watch for late immune interstitial nephritis
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.
The leading contributors to Atezolizumab’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on Atezolizumab; the PMIDs beside each name are up to three of their most recent papers on it, not the full count.
Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 83 clinical records among all 110 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.